The success of GLP-1 receptor agonists/analogues has transformed metabolic disease treatment while demonstrating the potential of engineered peptides to deliver long-acting, highly targeted therapies.

© 2026 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...